High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.
作者信息
Heatley Susan L, Sadras Teresa, Kok Chung H, Nievergall Eva, Quek Kelly, Dang Phuong, McClure Barbara, Venn Nicola, Moore Sarah, Suttle Jeffrey, Law Tamara, Ng Anthea, Muskovic Walter, Norris Murray D, Revesz Tamas, Osborn Michael, Moore Andrew S, Suppiah Ram, Fraser Chris, Alvaro Frank, Hughes Timothy P, Mullighan Charles G, Marshall Glenn M, Pozza Luciano Dalla, Yeung David T, Sutton Rosemary, White Deborah L
机构信息
Cancer Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
Discipline of Medicine, University of Adelaide, SA, Australia.
出版信息
Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21.
Abstract
摘要
相似文献
1
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.
Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21.
2
Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Semin Hematol. 2018 Oct;55(4):235-241. doi: 10.1053/j.seminhematol.2018.05.001. Epub 2018 May 29.
3
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.
Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16.
4
Philadelphia chromosome-positive acute lymphoblastic leukemia in China: a retrospective study from the Chinese Childhood Cancer Group.
Leuk Lymphoma. 2016 Nov;57(11):2696-8. doi: 10.3109/10428194.2016.1157872. Epub 2016 May 19.
5
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.
Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28.
6
Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
Leuk Res. 2017 Aug;59:136-141. doi: 10.1016/j.leukres.2017.05.021. Epub 2017 Jun 1.
7
[Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing with an anterior chamber lesion of the eye].
Rinsho Ketsueki. 2019;60(2):134-136. doi: 10.11406/rinketsu.60.134.
8
Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S10-S15. doi: 10.1016/j.clml.2017.03.296.
9
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
Am J Hematol. 2003 Nov;74(3):218-20. doi: 10.1002/ajh.10409.
10
T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26242. Epub 2016 Oct 26.
引用本文的文献
1
Identification of Molecular Subtypes of B-Cell Acute Lymphoblastic Leukemia in Mexican Children by Whole-Transcriptome Analysis.
Int J Mol Sci. 2025 Jul 21;26(14):7003. doi: 10.3390/ijms26147003.
2
Bridging the Gap: Cost-Effective Strategies for Detecting Ph-Like B-Lineage ALL in Resource-Limited Settings.
Mol Diagn Ther. 2025 May;29(3):329-344. doi: 10.1007/s40291-025-00775-9. Epub 2025 Mar 28.
3
Identification and validation of the optimal reference genes for standardizing the gene expression profiling diagnostic panel of Ph-like B-lineage acute lymphoblastic leukemia.
Clin Exp Med. 2023 Dec;23(8):4539-4551. doi: 10.1007/s10238-023-01131-z. Epub 2023 Jul 20.
4
'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
Br J Cancer. 2023 Jul;129(1):143-152. doi: 10.1038/s41416-023-02294-y. Epub 2023 May 8.
5
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Br J Cancer. 2022 Sep;127(5):908-915. doi: 10.1038/s41416-022-01806-6. Epub 2022 Jun 1.
6
Case Report: Precision Medicine Target Revealed by Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis.
Front Oncol. 2022 Apr 20;12:851572. doi: 10.3389/fonc.2022.851572. eCollection 2022.
7
Prognostic value of CD20 antigen mediated immune checkpoint inhibition in patients with acute or chronic lymphocytic leukemia: A protocol for systematic review.
Medicine (Baltimore). 2022 Feb 18;101(7):e28868. doi: 10.1097/MD.0000000000028868.
8
Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.
Int J Mol Sci. 2022 Mar 2;23(5):2755. doi: 10.3390/ijms23052755.
9
Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature.
Cancers (Basel). 2021 Nov 19;13(22):5814. doi: 10.3390/cancers13225814.
10
Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
Genes (Basel). 2021 May 1;12(5):687. doi: 10.3390/genes12050687.
本文引用的文献
1
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Blood. 2017 Jun 22;129(25):3352-3361. doi: 10.1182/blood-2016-12-758979. Epub 2017 Apr 13.
2
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.
3
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.
4
BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.
Haematologica. 2015 Sep;100(9):e354-7. doi: 10.3324/haematol.2015.124941. Epub 2015 Jun 4.
5
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.
6
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
J Clin Oncol. 2014 Sep 20;32(27):3012-20. doi: 10.1200/JCO.2014.55.4105.
7
A revised definition for cure of childhood acute lymphoblastic leukemia.
Leukemia. 2014 Dec;28(12):2336-43. doi: 10.1038/leu.2014.142. Epub 2014 Apr 30.
8
Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease.
PLoS One. 2013 Oct 11;8(10):e76455. doi: 10.1371/journal.pone.0076455. eCollection 2013.
9
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.
10
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.
Zotero 插件